Abstract

Late-life depression is associated with an increased risk for dementia but we have limited knowledge of the molecular mechanisms underlying this association. Here we investigated whether brain microRNAs, important posttranscriptional regulators of gene expression, contribute to this association. Late-life depressive symptoms were assessed annually in 300 participants of the Religious Orders Study and Rush Memory and Aging Project for a mean of 7 years. Participants underwent annual cognitive testing, clinical assessment of cognitive status, and uniform neuropathologic examination after death. microRNAs were profiled from the prefrontal cortex using NanoString platform in the discovery cohort and small RNA sequencing in the replication cohort. A global microRNA association study of late-life depressive symptoms was performed using linear mixed model adjusting for the potential confounding factors. Four brain microRNAs were associated with late-life depressive symptoms at adjusted p < 0.05: miR-484, miR-26b-5p, miR-30d-5p, and miR-197-3p. Lower expression levels of these miRNAs were associated having greater depressive symptoms. Furthermore, lower levels of miR-484 and miR-197-3p were associated with faster decline of cognition over time. Moreover, lower miR-484 level was associated with higher probability of having Alzheimer’s dementia. Importantly, the associations between miR-484 and depressive symptoms and Alzheimer’s dementia, respectively, were replicated in an independent cohort. Lastly, the predicted targets of miR-484 were enriched in a brain protein co-expression module involving synaptic transmission and regulation of synaptic plasticity. This study identified four brain microRNAs associated with late-life depressive symptoms assessed longitudinally. In addition, we found a molecular connection between late-life depression and dementia through miR-484.

Details

Title
Brain microRNAs associated with late-life depressive symptoms are also associated with cognitive trajectory and dementia
Author
Wingo, Thomas S 1   VIAFID ORCID Logo  ; Yang, Jingjing 2   VIAFID ORCID Logo  ; Fan, Wen 1 ; Min Canon Se 1 ; Gerasimov, Ekaterina Sergeevna 1 ; Adriana, Lori 3 ; Logsdon, Benjamin 4 ; Yao, Bing 2 ; Seyfried, Nicholas T 5 ; Lah, James J 1 ; Levey, Allan I 1 ; Boyle, Patricia A 6 ; Schneider, Julia A 6 ; De Jager Philip L 7   VIAFID ORCID Logo  ; Bennett, David A 6 ; Wingo, Aliza P 8   VIAFID ORCID Logo 

 Emory University School of Medicine, Department of Neurology, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502) 
 Emory University School of Medicine, Department of Human Genetics, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502) 
 Emory University School of Medicine, Department of Psychiatry, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502) 
 Sage Bionetworks, Seattle, USA (GRID:grid.430406.5) (ISNI:0000 0004 6023 5303) 
 Emory University School of Medicine, Department of Biochemistry, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502) 
 Rush University Medical Center, Rush Alzheimer’s Disease Center, Chicago, USA (GRID:grid.240684.c) (ISNI:0000 0001 0705 3621) 
 Columbia University Medical Center, Center for Translational and Computational Neuroimmunology, Department of Neurology, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675) 
 Emory University School of Medicine, Department of Psychiatry, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Atlanta VA Medical Center, Division of Mental Health, Decatur, USA (GRID:grid.414026.5) (ISNI:0000 0004 0419 4084) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20567944
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2352042988
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.